Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Profound Medical (PROF) Shares Outstanding (Weighted Average) (2018 - 2026)

Profound Medical has reported Shares Outstanding (Weighted Average) over the past 8 years, most recently at $30.2 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 22.08% year-over-year to $30.2 million; the TTM value through Dec 2025 reached $30.2 million, up 22.08%, while the annual FY2025 figure was $30.2 million, 22.08% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $30.2 million at Profound Medical, roughly flat from $30.1 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $222.8 billion in Q1 2022 and troughed at $772270.0 in Q4 2022.
  • A 5-year average of $22.9 billion and a median of $212.6 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Biggest five-year swings in Shares Outstanding (Weighted Average): soared 2642.9% in 2023 and later crashed 99.89% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $20.8 million in 2021, then crashed by 96.28% to $772270.0 in 2022, then soared by 2642.9% to $21.2 million in 2023, then rose by 16.91% to $24.8 million in 2024, then rose by 22.08% to $30.2 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for PROF at $30.2 million in Q4 2025, $30.1 million in Q3 2025, and $30.1 million in Q2 2025.